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Introduction: In patients with renal disorders, a sudden decrease in 
glomerular filtration rate (GFR) would not result in rapid rise 
concentrations of Creatinine. The present study aimed to assess diagnostic 
accuracy of serum Cystatin C as an appropriate alternative to serum 
Creatinine for early detection of Chronic Kidney Disease (CKD). 
Materials and Methods: In this study, 72 patients, 48 female and 24 male 
were selected. Serum Cystatin C and serum Creatinine were assayed, using 
enzyme-linked immunosorbent assay (ELISA) and routine methods, 
respectively. Glomerular filtration rate (eGFR) was estimated by Cockcroft 
and Gault formula. Receiver operating characteristics (ROC) analysis was 
adopted to evaluate diagnostic accuracy of serum Cystatin C and serum 
Creatinine. 
Results: Using Pearson's Correlation Coefficient analysis among 
Creatinine, Cystatin C and eGFR showed Serum Cystatin C was better than 
Creatinine. The sensitivity, specificity and AUC for Serum Cystatin C were 
0.88, 0.70 and 0.85, and for Serum Creatinine, they  were 0.60, 0.80 and 
0.68 respectively. 
Conclusion: Our results showed that in early stages of CKD, Cystatin C is 
a more accurate biomarker for kidney function than Creatinine 
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1. Introduction 
     Chronic kidney disease (CKD) is a long-
standing, progressive deterioration of 
kidney function with structural or functional 
abnormalities for 3 months or more. In 
advanced stages of CKD, permanent renal 
failure could be inevitable [1, 2]. By and 
large, factors which may increase the risk of 
chronic kidney disease are hypertension, 
diabetes and smoking [3]. High blood 
pressure affects kidney function which leads 
to kidney failure and approximately 40% of  
 
adults more than 25 years old have 
hypertension (BP ≥140 mmHg Systolic or 
90 mmHg diastolic) [4]. Renal failure and 
its irreversible consequences can be 
prevented by early diagnosis and careful 
management of existing conditions[5]. 
Therefore, identification of reliable and 
accurate biomarkers will improve the CKD 
diagnosis and treatment methods. Serum 
Creatinine has been widely used as the 
kidney function measurement in common 
clinical practices and yet, Creatinine 
concentration is indicated as a biomarker of 
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glomerular filtration rate (GFR) and cannot 
remain as a magnificent diagnostic tool for 
kidney function. The reason is that the 
blood Creatinine will not increase until 
when 50% of kidney function is damaged; 
moreover, it is affected by muscle mass, 
age, gender and race. [6]. The common 
biomarker, Creatinine, inability to detect the 
early reduction of GFR is risky especially 
when detecting CKD at early stages is 
substantial.  
Cystatin C has been proved to be the 
preferable biomarker compared to 
Creatinine in regard with renal function [7]. 
Cystatin C is a non-glycosylated 13-kD 
protein belonging to the cysteine 
superfamily of cysteine proteinase 
inhibitors and it is produced by all nucleated 
cells at a constant rate. Unlike Creatinine, 
the serum level of Cystatin C is not affected 
by age, sex, and muscle mass. Therefore, 
the plasma concentration of Cystatin C 
would be an accurate biomarker of subtle 
changes in renal function.[8]  
Unlike the normal kidney, blood levels of 
Cystatin C starts to rise when GFR 
decreases and kidneys are not working well. 
The reason is that Cystatin C is passed 
freely across the normal Glomerular 
membrane and is then completely 
reabsorbed and degraded in tubular 
epithelial cells; the glomerular filtration rate 
controls the plasma Cystatin C 
concentration. [9] The aim of the present 
study was evaluating the diagnostic 
accuracy of Cystatin C and comparing the 
accuracy of Cystatin C with that of the 
Creatinine. 
 
2. Materials and Methods 
     The study was carried out on 72 patients, 
aged between 40 to 70 years who referred to 
Shohada Tajrish Hospital for a chek-up over 
their kidney function. Ethical approval for 
this study was obtained from Shahid 
Beheshti University of Medical Sciences, 
Tehran, Iran. Informed consent was 
obtained from all participants before the 
study began, so records for age, height, 
weight and laboratory investigations were 
collected.  
In order to reduce the confounding 
variables, patients were excluded from the 
study if they had any chronic disease or 
increased levels serum Creatinine and urea. 
The serum and plasma were obtained from 
blood samples when they were fast. 
The obtained samples of serum and plasma 
were stored until the assessment time. For 
measurement of serum Cystatin C, an 
enzyme-linked immunosorbent assay 
(ELISA) method (Biovender, Norway) was 
used. Serum Creatinine was measured 
through standard method; moreover, the 
Cockcroft and Gault formula based on 
serum Creatinine concentration was used to 
calculate eGFR. 
eGFR (ml/min) =  ((140-age)*mass 
(kg)*(0.85 if female))/(72*scr(mg/dl)) 
 
2.1. Statistical Analysis:  
     Statistical analysis of the study was 
performed through using SPSS software 
(version 25.0). The continuous data was 
presented with mean ± SD and categorical 
data with frequencies. Difference between 
Non-CKD and CKD patients was compared 
by Chi-square and independent samples t 
tests and the association measurement 
between eGFR and other biomarkers were 
determined through using Pearson's 
coefficient. The best cut-off values of 
Cystatin C and Creatinine were calculated 
by Receiver operating characteristics (ROC) 
analysis to identify the CKD patients. 
 
3. Results 
     The study sample included 72 patients 
aged 40–70 years (66.7% male and 33.3% 
women). The mean of serum Creatinine and  
serum Cystatin C levels, eGFR and other 
biological characteristics are shown in table 
1. By using the independent samples t-test 
for age and weight, serum Cystatin C 
significant different level between non-
CKD and CKD groups were obtained 
(P < 0.05).  
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Using the Pearson's correlation coefficient, 
the eGFR correlation with serum Cystatin C 
was (r2= -0.451, p < 0.001) and serum 
Creatinine was (r2= -0.251, P = 0.033) 
which are both regarded as significantly 
high values. 
The best cut-off values based on the ROC 
analyses showed that the predictive power 
of serum Cystatin C is better than serum 
Creatinine for prediction of GFR < 78 
ml/min/1.73. Table 2 shows the AUCs, best 
cut-off values, sensitivity and specificity. 
 









Age 53.15  57.04 8.68 54.51 8.06 0.048 
Weight 82.68 13.60 72.89 11.47 79.28 13.65 0.002 
Creatinine 0.99 0.14 1.09 0.18 1.02 0.17 481.0 
Cystatin C 118.11 211.50 998.28 1014.52 423.72 744.96 <0.001 
Sex (M) 17 (36.2 7 (28) 24 (33.3) 0.058 
 
*mean SD          **no (%) 
 
Table 2. The ROC analysis for prediction ability of Creatinine and Cystatin C 
Biomarker Sensitivity Specificity  AUC Cut Point 
Creatinine 24844 .4844 0.68 1841 
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4. Discussion 
     Early detection and proper management 
of CKD can often help to prevent the 
kidney disease from getting worse [10]. 
Thus, by increasing the accuracy of 
biomarkers for early detection of 
individuals at progressive stage prediction 
and treatment of renal disease can be 
obtained. 
Creatinine is a common biomarker of 
kidney function which is produced in a 
constant rate by the body. However, it has 
several limitations one of which is not being 
a sensitive biomarker of GFR. Therefore, 
identification of early biomarker for kidney 
damage is imperative. Several studies have 
demonstrated that among the other 
biomarkers, Cystatin C is the most accurate  
biomarker for early diagnosing of CKD. 
[11]  
Serum Cystatin C as a magnificent 
biomarker of renal functions rises rapidly 
during minor glomerular damage. In 
addition, elevated levels of Cystatin C are 
associated with increased cardiovascular 
risk. In normal kidneys, Cystatin C levels 
are 0.8–1.1 mg/L and 0.6–1.1 mg/L for men 
and women, respectively. [12] 
In the present study, the predictive accuracy 
of Cystatin C for individuals was shown in 
early stages of CKD as an improved 
diagnostic marker of GFR in comparison 
with the current marker. It was revealed that 
the mean of serum Cystatin C level was 
significantly increased in patients with renal 
impairment in comparison with the non-
CKD patients.  
These findings are in accordance with the 
research of Michele Mussap et al who also 
reported early and significantly higher 
Serum Cystatin C levels than serum 
Creatinine in 52 CKD patients.[13] 
While Serum Cystatin C had higher 
correlation with eGFR than serum 
Creatinine, the present study revealed that 
inverse association with eGFR and Serum 
Cystatin C is significant (r2= -0.451, 
p < 0.001). Similar findings were reported 
by Weihong Zhao et al which demonstrated 
the significant correlation between eGFR 
and Serum Cystatin C. [14] 
In a study conducted by Kumaresan et al, 
the ROC analysis showed that the AUC for 
Cystatin C and Creatinine was 0.77 and 
0.59, respectively [15]. In this study, the 
AUC of 85% demonstrated that Cystatin C 
has a higher accuracy for predicting 
GFR<78 ml/min than Creatinine (auc= 
68%). 
The optimal cut-off points of Cystatin C and 
Creatinine for detecting early stage of CKD 
were determined. Cutoff value for Cystatin 
C was 100 ng/ml (sensitivity= 0.88; 
specificity= 0.70) and for Creatinine was 
1.05 mg/dl (sensitivity= 0.60; specificity= 
0.80). In Gerbes et al study the optimal cut 
off concentrations for Cystatin C and 
Creatinine were 1.0 mg/l (sensitivity= 0.69; 
specificity= 0.56) and 0.9 mg/100 ml 
(sensitivity= 0.45; specificity= 0.70), 
respectively [16]. These results are 
consistent with the present study’s finding 
which proved tshe higher sensitivity for 
Cystatin C in comparison with Creatinine. 
 
5. Conclusion 
     This study’s findings indicated that the 
diagnostic power of serum Cystatin C for 
early detection of CKD is higher than 
Creatinine. Therefore, Cystatin C with or 
without Creatinine could be used as an 
appropriate diagnosing marker of CKD. 
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